{"id":"https://openalex.org/W4396587512","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po3-06-14","title":"Abstract PO3-06-14: Phase I/II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer","display_name":"Abstract PO3-06-14: Phase I/II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer","publication_year":2024,"publication_date":"2024-05-02","ids":{"openalex":"https://openalex.org/W4396587512","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po3-06-14"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs23-po3-06-14","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po3-06-14","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.sabcs23-po3-06-14","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052187738","display_name":"Saranya Chumsri","orcid":"https://orcid.org/0000-0001-7117-1446","observed_orcids":["https://orcid.org/0000-0001-7117-1446"]},"institutions":[{"id":"https://openalex.org/I4210146710","display_name":"Mayo Clinic in Florida","ror":"https://ror.org/03zzw1w08","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210146710"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Saranya Chumsri","raw_affiliation_strings":["1Mayo Clinic, Jacksonville,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Mayo Clinic, Jacksonville,","institution_ids":["https://openalex.org/I4210146710"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076758389","display_name":"Joseph J. Larson","orcid":"https://orcid.org/0000-0001-8372-0465","observed_orcids":["https://orcid.org/0000-0001-8372-0465"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Larson","raw_affiliation_strings":["2Mayo Clinic,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Mayo Clinic,","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005317276","display_name":"Daniel L. Adams","orcid":"https://orcid.org/0000-0002-1916-9637","observed_orcids":["https://orcid.org/0000-0002-1916-9637"]},"institutions":[{"id":"https://openalex.org/I4210118300","display_name":"Creatv MicroTech (United States)","ror":"https://ror.org/02htbg024","country_code":"US","type":"company","lineage":["https://openalex.org/I4210118300"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Adams","raw_affiliation_strings":["3Creatv Microtech, Inc., Monmouth Junction, New Jersey, United States,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Creatv Microtech, Inc., Monmouth Junction, New Jersey, United States,","institution_ids":["https://openalex.org/I4210118300"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085436504","display_name":"Kathleen Tenner","orcid":"https://orcid.org/0000-0003-4607-4286","observed_orcids":["https://orcid.org/0000-0003-4607-4286"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kathleen Tenner","raw_affiliation_strings":["2Mayo Clinic,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Mayo Clinic,","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021852926","display_name":"Cha\u2010Mei Tang","orcid":"https://orcid.org/0000-0003-3017-0732","observed_orcids":["https://orcid.org/0000-0003-3017-0732"]},"institutions":[{"id":"https://openalex.org/I4210118300","display_name":"Creatv MicroTech (United States)","ror":"https://ror.org/02htbg024","country_code":"US","type":"company","lineage":["https://openalex.org/I4210118300"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cha-Mei Tang","raw_affiliation_strings":["4Creatv MicroTech, Inc.,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Creatv MicroTech, Inc.,","institution_ids":["https://openalex.org/I4210118300"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078223091","display_name":"Morgan T. Weidner","orcid":"https://orcid.org/0009-0003-0550-6940","observed_orcids":["https://orcid.org/0009-0003-0550-6940"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Morgan Weidner","raw_affiliation_strings":["2Mayo Clinic,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Mayo Clinic,","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Amanda Arnold","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amanda Arnold","raw_affiliation_strings":["2Mayo Clinic,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Mayo Clinic,","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061165370","display_name":"Dana L. Haley","orcid":"https://orcid.org/0009-0000-7800-2370","observed_orcids":["https://orcid.org/0009-0000-7800-2370"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dana Haley","raw_affiliation_strings":["2Mayo Clinic,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Mayo Clinic,","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012173490","display_name":"Pooja Prem Advani","orcid":"https://orcid.org/0009-0007-5470-3149","observed_orcids":["https://orcid.org/0009-0007-5470-3149"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pooja Advani","raw_affiliation_strings":["2Mayo Clinic,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Mayo Clinic,","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051516231","display_name":"Kostandinos Sideras","orcid":"https://orcid.org/0000-0002-4698-2105","observed_orcids":["https://orcid.org/0000-0002-4698-2105"]},"institutions":[{"id":"https://openalex.org/I4210146710","display_name":"Mayo Clinic in Florida","ror":"https://ror.org/03zzw1w08","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210146710"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kostandinos Sideras","raw_affiliation_strings":["5Mayo Clinic, Jacksonville, Florida, United States,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Mayo Clinic, Jacksonville, Florida, United States,","institution_ids":["https://openalex.org/I4210146710"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027821205","display_name":"Alvaro Moreno\u2010Aspitia","orcid":"https://orcid.org/0000-0002-2317-2580","observed_orcids":["https://orcid.org/0000-0002-2317-2580"]},"institutions":[{"id":"https://openalex.org/I4210146710","display_name":"Mayo Clinic in Florida","ror":"https://ror.org/03zzw1w08","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210146710"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alvaro Moreno-Aspitia","raw_affiliation_strings":["5Mayo Clinic, Jacksonville, Florida, United States,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Mayo Clinic, Jacksonville, Florida, United States,","institution_ids":["https://openalex.org/I4210146710"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065306642","display_name":"Edith A. Perez","orcid":"https://orcid.org/0000-0002-5037-6677","observed_orcids":["https://orcid.org/0000-0002-5037-6677","https://orcid.org/0000-0001-7009-7467"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Edith Perez","raw_affiliation_strings":["6Mayo","Mayo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Mayo","institution_ids":[]},{"raw_affiliation_string":"Mayo","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5031005364","display_name":"Keith L. Knutson","orcid":"https://orcid.org/0000-0001-9932-4467","observed_orcids":["https://orcid.org/0000-0001-9932-4467"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Keith Knutson","raw_affiliation_strings":["2Mayo Clinic,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Mayo Clinic,","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"84","issue":"9_Supplement","first_page":"PO3","last_page":"06"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.5493000149726868,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.5493000149726868,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.4147999882698059,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.013000000268220901,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9940000176429749},{"id":"https://openalex.org/keywords/binimetinib","display_name":"binimetinib","score":1.0},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.9570000171661377},{"id":"https://openalex.org/keywords/ras-mapk-pathway","display_name":"RAS/MAPK pathway","score":0.8489999771118164},{"id":"https://openalex.org/keywords/mek-inhibitors","display_name":"MEK inhibitors","score":0.8769999742507935},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7099999785423279},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.7960000038146973},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.9900000095367432},{"id":"https://openalex.org/keywords/circulating-tumor-cells","display_name":"circulating tumor cells","score":0.9380000233650208},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.42899999022483826},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7310000061988831},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.6919999718666077},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.6050000190734863},{"id":"https://openalex.org/keywords/locally-advanced-breast-cancer","display_name":"locally advanced breast cancer","score":0.9629999995231628}],"concepts":[{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.7590821981430054},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7479662895202637},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.5637708306312561},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5493074655532837},{"id":"https://openalex.org/C2780110267","wikidata":"https://www.wikidata.org/wiki/Q7843332","display_name":"Triple-negative breast cancer","level":4,"score":0.535456657409668},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5076884031295776},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48265916109085083},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.45929592847824097},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.42419418692588806},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.09526795148849487}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs23-po3-06-14","doi":"https://doi.org/10.1158/1538-7445.sabcs23-po3-06-14","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.sabcs23-po3-06-14","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4322760455","https://openalex.org/W3005022366","https://openalex.org/W4379985133","https://openalex.org/W4408212925","https://openalex.org/W3179751602","https://openalex.org/W2791885889","https://openalex.org/W4414085154","https://openalex.org/W2798076154","https://openalex.org/W2990502619","https://openalex.org/W2593885430"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Activation":[2],"of":[3,26,49,175,187,299,315,328,590,617,652,673],"the":[4,24,203,502,539,587,615,674],"RAS/MAPK":[5],"pathway":[6],"is":[7,513],"associated":[8,342,369,427,468,493,515,603],"with":[9,30,37,44,58,69,109,146,171,193,214,224,242,293,301,309,317,343,370,380,405,428,469,494,516,534,538,556,604,656,661],"reduced":[10],"tumor-infiltrating":[11],"lymphocytes":[12,118],"and":[13,77,92,126,132,143,148,159,200,227,247,278,326,357,374,390,407,415,447,459,486,527,559,598],"poor":[14],"outcomes":[15],"in":[16,28,89,99,106,184,190,207,266,289,307,338,363,411,417,443,449,463,477,488,497,504,511,519,554,563,570,595,654,659],"triple-negative":[17,667],"breast":[18,668],"cancer":[19,669],"(TNBC).":[20],"This":[21],"trial":[22],"evaluated":[23,402],"efficacy":[25,616],"pembrolizumab":[27,653],"combination":[29,655],"binimetinib,":[31],"a":[32,55,172,384,475,582],"MEK":[33],"inhibitor.":[34],"Methods:":[35],"Patients":[36],"unresectable":[38,662],"locally":[39,663],"advanced":[40,664],"or":[41,665],"metastatic":[42,666],"TNBC":[43],"\u2264":[45],"3":[46,195,216],"prior":[47],"lines":[48],"therapy":[50],"were":[51,64,120,138,162,169,220,228,297,366,465,492,600],"enrolled.":[52],"Treatment":[53],"includes":[54],"2-week":[56],"run-in":[57],"binimetinib":[59,70,528,658],"followed":[60],"by":[61],"pembrolizumab.":[62],"There":[63,219,296],"2":[65,185,391],"dose":[66],"levels":[67],"(DL)":[68],"at":[71,74,80,529],"45":[72],"mg":[73,79,531],"DL":[75,81,191,208,225],"0":[76,382],"30":[78,530],"-1.":[82],"A":[83],"standard":[84],"3+3":[85],"design":[86,96],"was":[87,97,104,182,211,237,260,271,280,287,311,341,425,551],"used":[88,98,163],"Phase":[90,100,649],"I,":[91],"Simon\u2019s":[93],"two-stage":[94],"Optimal":[95],"II.":[101],"PD-L1":[102,147,302,318,336,410,460,487,509,517,560,568],"22C3":[103],"performed":[105],"archival":[107,339,364,520,576],"samples":[108],"CPS":[110,303],"\u2265":[111,257,304,333,387],"10":[112],"considered":[113],"as":[114,581],"positive":[115],"(PD-L1+).":[116],"Tumor-infiltrating":[117],"(TILs)":[119],"quantified":[121],"into":[122],"0,":[123,192],"1,":[124],"2,":[125],"3+.":[127],"Circulating":[128],"tumor":[129,577],"cells":[130,136],"(CTC)":[131],"circulating":[133],"cancer-associated":[134],"macrophage-like":[135],"(CAML)":[137],"isolated":[139],"using":[140],"CellSieve":[141],"microfilters":[142],"immunofluorescently":[144],"labeled":[145],"p-ERK.":[149],"Wilcoxon":[150],"rank":[151],"sum":[152],"test,":[153,155],"Chi-square":[154],"Cox":[156,472],"regression":[157,473],"model,":[158],"Spearman":[160],"correlation":[161,523],"for":[164,230],"analysis.":[165],"Results:":[166],"22":[167],"patients":[168,189,206,222,267,292,300,308,316,329,392,555,564,660],"enrolled":[170],"median":[173],"age":[174],"58":[176],"years":[177],"old.":[178],"Dose-limiting":[179],"toxicity":[180],"(DLT)":[181],"observed":[183,288,552],"out":[186],"4":[188,248],"grade":[194,215],"ALT":[196],"abnormality,":[197],"flank":[198],"pain,":[199],"nausea.":[201],"In":[202],"next":[204],"6":[205],"-1,":[209],"there":[210],"1":[212,243,423],"DLT":[213],"AST/ALT":[217],"abnormality.":[218],"17":[221],"treated":[223],"-1":[226],"evaluable":[229],"response.":[231,399],"The":[232,252],"objective":[233,324,398],"response":[234,245,286,325],"rate":[235,255],"(ORR)":[236],"29.41%":[238],"(95%":[239,262,273,282],"CI:":[240,263,274,283],"10.31-55.9)":[241],"complete":[244],"(CR)":[246],"partial":[249],"responses":[250],"(PR).":[251],"clinical":[253,331,588,608],"benefit":[254,332,589],"(CBR":[256],"24":[258,334,388],"weeks)":[259],"35.29%":[261],"14.21-61.67).":[264],"ORR":[265,306,344],"without":[268,565],"liver":[269,294,566],"metastases":[270],"55.56%":[272],"21.20":[275],"-":[276],"86.30)":[277],"CBR":[279,349,371],"66.67%":[281],"29.93-92.51).":[284],"No":[285],"all":[290],"5":[291],"metastases.":[295,567],"40.9%":[298],"10.":[305],"PD-L1+":[310],"80%.":[312],"However,":[313,430,508],"11.1%":[314],"negative":[319],"tumors":[320],"also":[321,367,395,601],"had":[322,330,383,396],"an":[323,397],"44.4%":[327],"weeks.":[335],"expression":[337,510,518,569],"tissue":[340,365,521,578],"(p":[345,350,360,372,376,413,420,436,440,445,454,457,461,480,484,490,506],"0.032)":[346],"but":[347,500],"not":[348,368,466,501,514],"0.198),":[351],"progression-free":[352],"survival":[353,359,499],"(PFS,":[354],"p":[355],"0.373),":[356],"overall":[358,498],"0.348).":[361],"TILs":[362,381,393,558],"0.155)":[373],"PFS":[375],"0.157).":[377],"One":[378],"patient":[379],"stable":[385],"disease":[386],"weeks":[389],"1+":[394],"We":[400],"further":[401,613],"blood-based":[403],"biomarkers":[404],"CTC":[406,432,450],"CAML.":[408],"Baseline":[409],"CAML":[412,418,434,438,444,452,464,478,482,489,512,573,596],"0.04)":[414],"decline":[416],"size":[419,439,483],"0.02)":[421],"after":[422],"cycle":[424],"significantly":[426,467,602],"CBR.":[429],"baseline":[431],"count,":[433,451],"count":[435,453,479,597],"0.64),":[437],"0.46),":[441],"p-ERK":[442,456,505],"0.23),":[446],"changes":[448],"0.83),":[455],"0.07),":[458],"0.08)":[462],"responses.":[470,605],"Using":[471],"analysis,":[474],"reduction":[476,503],"0.02),":[481],"0.01),":[485],"0.03)":[491],"significant":[495],"improvement":[496],"0.6).":[507],"(Spearman":[522],"0.13).":[524],"Conclusions:":[525],"Pembrolizumab":[526],"are":[532,610],"safe":[533],"manageable":[535],"toxicities.":[536],"Consistent":[537],"preclinical":[540],"data":[541],"that":[542],"MEKi":[543],"can":[544],"restore":[545],"T":[546],"cell":[547],"function,":[548],"promising":[549],"activity":[550],"even":[553],"low":[557],"negative,":[561],"particularly":[562],"peripheral":[571],"blood":[572],"rather":[574],"than":[575],"may":[579],"serve":[580],"better":[583],"biomarker":[584],"to":[585,612],"predict":[586],"this":[591,618],"combination.":[592,620],"Early":[593],"reductions":[594],"size,":[599],"Future":[606],"larger":[607],"trials":[609],"warranted":[611],"evaluate":[614],"chemotherapy-free":[619],"Citation":[621],"Format:":[622],"Saranya":[623],"Chumsri,":[624],"Joseph":[625],"Larson,":[626],"Daniel":[627],"Adams,":[628],"Kathleen":[629],"Tenner,":[630],"Cha-Mei":[631],"Tang,":[632],"Morgan":[633],"Weidner,":[634],"Amanda":[635],"Arnold,":[636],"Dana":[637],"Haley,":[638],"Pooja":[639],"Advani,":[640],"Kostandinos":[641],"Sideras,":[642],"Alvaro":[643],"Moreno-Aspitia,":[644],"Edith":[645],"Perez,":[646],"Keith":[647],"Knutson.":[648],"I/II":[650],"study":[651],"oral":[657],"[abstract].":[670],"In:":[671],"Proceedings":[672],"2023":[675,681],"San":[676,684],"Antonio":[677],"Breast":[678],"Cancer":[679,690],"Symposium;":[680],"Dec":[682],"5-9;":[683],"Antonio,":[685],"TX.":[686],"Philadelphia":[687],"(PA):":[688],"AACR;":[689],"Res":[691],"2024;84(9":[692],"Suppl):Abstract":[693],"nr":[694],"PO3-06-14.":[695]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2024-05-03T00:00:00"}